Shahram Seyedin-Noor
Founder and General Partner @ Civilization Ventures
San Francisco, United States
Shahram Seyedin-Noor is a seed investor at Civilization Ventures in San Francisco focused on Health Care and Biotechnology. Shahram Seyedin-Noor is the Founder and General Partner of Civilization Ventures. He attended Pomona College.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Shahram Seyedin-Noor invests in
Stages Shahram Seyedin-Noor invests in
Countries Shahram Seyedin-Noor invests in
Investment Focus
Industry
- Health Care 2 (40%)
- Biotechnology 1 (20%)
Stage
- Seed 1 (20%)
- Series A 1 (20%)
- Series B 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Foresight Diagnostics
|
Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $33M / Series B / Jul 30, 2024 | |
|
Foresight Diagnostics
|
Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $58.8M / Series B / Apr 27, 2023 | |
|
Wyndly
|
Wyndly is fixing allergies. We give you lifelong allergy relief with personalized, prescription treatment and phenomenal online care. We’re making an allergy-free life easy and accessible to the 60 million Americans who suffer from environmental allergies. | $2M / Seed / Feb 08, 2023 | |
|
Foresight Diagnostics
|
Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $12.5M / Series A / Jun 02, 2021 | |
|
Foresight Diagnostics
|
Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $12.5M / Series A / Dec 12, 2020 |
Co-Investors
Foresite Capital
6 deals together
Bluebird Ventures
3 deals together
Pear VC
3 deals together
Agent Capital
2 deals together
Stanford University
2 deals together
The CU Healthcare Innovation Fund
2 deals together
About Civilization Ventures
Civilization Ventures invests in visionary founders that are leading the future of health tech and biology-driven innovation. We aim to be the first check and lead investor in highly disruptive companies across digital health, synthetic biology, diagnostics, 3D (bio) printing, and AI/ software-enabled health tech. Our team comprises serialentrepreneurs and industry thought leaders who work tirelessly to help each of our portfolio companies succeed.
Civilization Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Shahram Seyedin-Noor
Founder and General Partner
|
|||
|
Zoya Khan
Analyst
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Shahram Seyedin-Noor invest in?
Shahram Seyedin-Noor invests primarily in Health Care and Biotechnology startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Shahram Seyedin-Noor last invest?
The most recent investment recorded for Shahram Seyedin-Noor closed in Jul 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
